<unk>  (EPD), is a treatment for allergies developed in the 1960s by Dr. Leonard M. McEwen in the United Kingdom. EPD uses much lower doses of antigens than conventional<unk>  treatment paired with the<unk>  β-glucuronidase. EPD is approved in the United Kingdom for the treatment of hay fever, food allergy and intolerance and environmental allergies. EPD was developed for the treatment of autoimmune disease by the United Kingdom company Epidyme which was owned by Dr. McEwen and had been granted a United Kingdom patent. Despite encouraging results in an experimental model of rheumatoid arthritis, the company was placed into liquidation in April 2010.
Enzyme potentiated desensitization
P-i mechanism
Reverse tolerance
Synaptic pharmacology
Inverse agonist
Gateway drug effect
New chemical entity
Abscopal effect